Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05774704 · ClinicalTrials.gov registry record · Phase 1

Curcumin and Retinal Study

A Phase 1 study of Gut Microbiome and Safety, sponsored by Texas Tech University Health Sciences Center.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT05774704 is a Phase 1 study of Gut Microbiome and Safety that is actively recruiting participants, run by Texas Tech University Health Sciences Center. The registered enrollment target is 60 participants, below the 265-participant average among 22 other Gut Microbiome trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05774704, a Phase 1 study of Gut Microbiome and Safety, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.

Interventions

  • DRUG Low curcumin group
  • DRUG High curcumin group

Study Locations (1)

Texas

  • Texas Tech University Health Sciences Center - Lubbock

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-08-21
Est. Completion 2026-12-31
Phase Phase 1

What the Registry Record Tells You About NCT05774704

The ClinicalTrials.gov registry entry for NCT05774704 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 265-participant average among 22 other Gut Microbiome trials with a reported enrollment target (77% lower). The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gut Microbiome appearing as the primary indexed condition, and to 2 interventions - of which Low curcumin group is the first listed.

NCT05774704 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05774704 about?

NCT05774704 is a clinical study titled "Curcumin and Retinal Study". To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.

What is the current status of trial NCT05774704?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-08-21. Estimated completion is 2026-12-31.

What conditions does trial NCT05774704 study?

This clinical trial studies the following conditions: Gut Microbiome, Safety, Bioavailability.

What interventions are being tested in trial NCT05774704?

The interventions under investigation include: Low curcumin group (DRUG), High curcumin group (DRUG).

Who is sponsoring clinical trial NCT05774704?

This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05774704 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gut Microbiome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.